Auspherix, a biopharmaceutical spin-out of University of Technology Sydney (UTS), has raised an additional AU$1m ($880,000) to top up its series A from Australia’s Medical Research Commercialisation Fund. The fund had previously invested AU$1m.
Auspherix, which has developed an anti-infective drug discovery programme, was spun out in 2013. Its technology could allow the development of antibiotics capable of treating resistant bacterial diseases. The company was founded by Ian Charles, director of the university’s ithree institute, and Dagmar Alber, senior research…
